The institute originally began reviewing Lynparza in this setting in 2018 but ended its review due to lack of evidence.

MOMA Therapeutics on Wednesday said it added the next-generation PARP1 inhibitor MOMA-989 to its pipeline of drug candidates and anticipates filing an investigational new drug application by year end ...

The biotech wants to create one-time, potentially curative treatments for rheumatoid arthritis and other autoimmune diseases by editing the HLA gene.

The French firm will use the proceeds to advance its ALIGATER platform for delivering genetic payloads and move its preclinical assets toward the clinic.